-
Shandong Buchang Partners with REMD Bio for Bispecific Antibody Development
•
China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) has announced a co-development and licensing agreement with US-headquartered REMD Biotherapeutics Inc. and its subsidiary Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. Under the agreement, REMD Bio will grant Luzhou Buchang an exclusive license for REMD-290 in mainland China and Russia. Agreement Details…
-
Eucure Biopharma Partners with ISU ABXIS to Develop Tri-Specific Antibodies Using YH003
•
Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen, has entered into a partnership agreement with South Korea-based ISU ABXIS Co., Ltd (ISU ABXIS, KOSDAQ: 086890). Under the agreement, ISU ABXIS has been granted the use of Eucure’s YH003 sequence to develop multiple tri-specific antibodies for the…
-
Zhejiang Medicine’s ARX788 Advances to Phase II Study for HER2-Positive Cholangiocarcinoma
•
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) has received approval from the National Medical Products Administration (NMPA) to conduct a Phase II clinical study assessing the efficacy and safety of its ARX788, an anti-HER2 monoclonal antibody conjugate with AS269, in patients with HER2-positive cholangiocarcinoma. This approval marks a significant step…
-
Simcere’s SIM0235 Begins US Phase I Trial for Anti-Tumor Therapy
•
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the enrollment of the first patient in a Phase I clinical study for its novel anti-tumor drug candidate SIM0235 (formerly SIM1811-03) in the United States. This marks a significant milestone in the global development of the drug. SIM0235: Mechanism and PotentialSIM0235 is…
-
China’s National Plan to Combat Microbial Drug Resistance Released
•
The National Health Commission (NHC), Ministry of Education, Ministry of Science and Technology, and 10 other bureaus have released the “National Action Plan for Combating Microbial Drug Resistance (2022-2025).” The plan outlines general requirements, main objectives, key tasks, and security measures to address the growing challenge of microbial drug resistance.…
-
Sanofi’s Q3 Sales Rise 9% on Dupixent and Flu Vaccine
•
French pharmaceutical major Sanofi (NASDAQ: SNY) released its Q3 2022 financial report, recording EUR 12.482 billion (USD 12.394 billion) in global net sales, up 9% year-on-year (YOY) in constant exchange rates. The growth was driven by strong performances from Dupixent (dupilumab) and its flu vaccine. Within the total sales, the…
-
Novartis’ Cosentyx Gains Approval for New Doses in China
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced receiving marketing approval for two new specifications of Cosentyx (secukinumab) in China. The new 300mg and 75mg prefilled syringe forms are approved for pediatric psoriasis in patients aged six years and above with moderate to severe plaque psoriasis eligible for systemic treatment…
-
XtalPi Partners with Janssen to Accelerate Drug Discovery
•
China-based XtalPi, Inc. has announced a research collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to deliver chemical matter with validated binding affinities and desirable property profiles. The collaboration was facilitated by Johnson & Johnson Innovation LLC. Collaboration DetailsUnder the agreement, XtalPi will…
